D.E. Shaw & Co
ACET icon

D.E. Shaw & Co’s Adicet Bio ACET Stock Holding History

D.E. Shaw & Co’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,387
Closed -$13.5K – 4515
2025
Q2 		$13.5K Sell
1,387
-30,205
-96% -$319K ﹤0.01% 4243
2025
Q1 		$382K Sell
31,592
-21,350
-40% -$305K ﹤0.01% 3641
2024
Q4 		$815K Sell
52,942
-4,375
-8% -$82.6K ﹤0.01% 3325
2024
Q3 		$1.32M Buy
57,317
+5,065
+10% +$113K ﹤0.01% 3062
2024
Q2 		$1.01M Buy
52,252
+31,880
+156% +$854K ﹤0.01% 3202
2024
Q1 		$766K Sell
20,372
-1,292
-6% -$53.4K ﹤0.01% 3259
2023
Q4 		$655K Buy
21,664
+6,359
+42% +$139K ﹤0.01% 3386
2023
Q3 		$335K Buy
15,305
+13,339
+678% +$471K ﹤0.01% 3576
2023
Q2 		$76.4K Sell
1,966
-822
-29% -$72.5K ﹤0.01% 3851
2023
Q1 		$257K Buy
+2,788
New +$350K ﹤0.01% 3806
2022
Q4 		– Sell
-7,022
Closed -$1.6M – 4828
2022
Q3 		$1.6M Sell
7,022
-13,716
-66% -$3.48M ﹤0.01% 3204
2022
Q2 		$4.84M Buy
20,738
+6,918
+50% +$1.52M 0.01% 2161
2022
Q1 		$4.42M Buy
13,820
+541
+4% +$124K ﹤0.01% 2455
2021
Q4 		$3.72M Buy
13,279
+10,537
+384% +$1.81M ﹤0.01% 2728
2021
Q3 		$344K Sell
2,742
-1,760
-39% -$218K ﹤0.01% 4283
2021
Q2 		$741K Buy
4,502
+2,472
+122% +$504K ﹤0.01% 3780
2021
Q1 		$425K Buy
2,030
+498
+33% +$114K ﹤0.01% 3577
2020
Q4 		$344K Buy
1,532
+764
+99% +$156K ﹤0.01% 3552
2020
Q3 		$146K Sell
768
-839
-52% -$212K ﹤0.01% 3656
2020
Q2 		$387K Buy
+1,607
New +$316K ﹤0.01% 3512
2020
Q1 		– Sell
-1,465
Closed -$245K – 3875
2019
Q4 		$245K Buy
+1,465
New +$742K ﹤0.01% 3716

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

D.E. Shaw & Co's ACET Position: Q3 2025 in Review

D.E. Shaw & Co sold out of Adicet Bio (ACET) in Q3 2025, closing a stake of 1,387 shares — an estimated $13.5K sold.

D.E. Shaw & Co first reported a position in ACET in Q4 2019 and held it in 21 quarters. The position peaked at $4.84M in Q2 2022. 54 funds tracked by Wall St. Rank hold ACET as of Q3 2025.

  • D.E. Shaw & Co reported no remaining Adicet Bio position as of Q3 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,387 Adicet Bio shares in Q3 2025, an estimated $13.5K.
  • D.E. Shaw & Co first reported a position in Adicet Bio in Q4 2019 and held it in 21 quarters.
  • D.E. Shaw & Co's Adicet Bio position peaked at $4.84M in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2025.

Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.